This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, M.
Right arrow Articles by Sato, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, M.
Right arrow Articles by Sato, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 1998, p. 3044-3046, Vol. 42, No. 11
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Quinolone Resistance Mutations in the GrlB Protein of Staphylococcus aureus

Mayumi Tanaka,* Yoshikuni Onodera, Yoko Uchida, and Kenichi Sato

New Product Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., Edogawa-ku, Tokyo 134-8630, Japan

Received 9 June 1998/Returned for modification 4 August 1998/Accepted 1 September 1998

Two altered GrlB proteins (one with an Asp-432right-arrowAsn alteration and one with an Asn-470right-arrowAsp alteration) of Staphylococcus aureus were purified as fusion proteins to maltose-binding protein. The 50% inhibitory concentrations of levofloxacin were 14 and 3.4 µg/ml against topoisomerase IV containing GrlB proteins with alterations at positions 432 and 470, respectively. These results suggest that the alteration of Asp to Asn at position 432 may be responsible for quinolone resistance.

* Corresponding author. Mailing address: New Product Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., 16-13 Kitakasai 1-Chome, Edogawa-ku, Tokyo 134-8630, Japan. Phone: 81-3-3680-0151, ext. 5810. Fax: 81-3-5696-8344. E-mail: tanakpmj{at}daiichipharm.co.jp.

Antimicrobial Agents and Chemotherapy, November 1998, p. 3044-3046, Vol. 42, No. 11
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Campion, J. J., McNamara, P. J., Evans, M. E. (2004). Evolution of Ciprofloxacin-Resistant Staphylococcus aureus in In Vitro Pharmacokinetic Environments. Antimicrob. Agents Chemother. 48: 4733-4744 [Abstract] [Full Text]  
  • Ince, D., Hooper, D. C. (2001). Mechanisms and Frequency of Resistance to Gatifloxacin in Comparison to AM-1121 and Ciprofloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 2755-2764 [Abstract] [Full Text]  
  • Akasaka, T., Tanaka, M., Yamaguchi, A., Sato, K. (2001). Type II Topoisomerase Mutations in Fluoroquinolone-Resistant Clinical Strains of Pseudomonas aeruginosa Isolated in 1998 and 1999: Role of Target Enzyme in Mechanism of Fluoroquinolone Resistance. Antimicrob. Agents Chemother. 45: 2263-2268 [Abstract] [Full Text]  
  • Linde, H.-J., Schmidt, M., Fuchs, E., Reischl, U., Niller, H.-H., Lehn, N. (2001). In Vitro Activities of Six Quinolones and Mechanisms of Resistance in Staphylococcus aureus and Coagulase-Negative Staphylococci. Antimicrob. Agents Chemother. 45: 1553-1557 [Abstract] [Full Text]  
  • Onodera, Y., Sato, K. (1999). Molecular Cloning of the gyrA and gyrB Genes of Bacteroides fragilis Encoding DNA Gyrase. Antimicrob. Agents Chemother. 43: 2423-2429 [Abstract] [Full Text]  
  • Saiki, A. Y. C., Shen, L. L., Chen, C.-M., Baranowski, J., Lerner, C. G. (1999). DNA Cleavage Activities of Staphylococcus aureus Gyrase and Topoisomerase IV Stimulated by Quinolones and 2-Pyridones. Antimicrob. Agents Chemother. 43: 1574-1577 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»